Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | mitogen-activated protein kinase 11 | References | |
Homo sapiens | mitogen-activated protein kinase 14 | References | |
Homo sapiens | mitogen-activated protein kinase 12 | References | |
Homo sapiens | mitogen-activated protein kinase 13 | Starlite/ChEMBL | References |
Mus musculus | mitogen-activated protein kinase 14 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | mitogen-activated protein kinase 5 | mitogen-activated protein kinase 14 | 360 aa | 336 aa | 33.3 % |
Trypanosoma brucei | mitogen-activated protein kinase 5 | mitogen-activated protein kinase 12 | 357 aa | 362 aa | 30.1 % |
Trypanosoma brucei | mitogen-activated protein kinase 5 | mitogen-activated protein kinase 13 | 365 aa | 366 aa | 30.1 % |
Trypanosoma brucei | mitogen-activated protein kinase 5 | mitogen-activated protein kinase 14 | 360 aa | 336 aa | 33.3 % |
Trypanosoma brucei | mitogen-activated protein kinase 5 | mitogen-activated protein kinase 11 | 364 aa | 361 aa | 33.0 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | uridine phosphorylase 1 | 0.2254 | 1 | 1 |
Echinococcus multilocularis | uridine phosphorylase 1 | 0.2254 | 1 | 1 |
Leishmania major | mitogen-activated protein kinase 3, putative,map kinase 3, putative | 0.0609 | 0 | 0.5 |
Trypanosoma brucei | mitogen-activated protein kinase 3, putative | 0.0609 | 0 | 0.5 |
Schistosoma mansoni | uridine phosphorylase | 0.2254 | 1 | 0.5 |
Loa Loa (eye worm) | uridine phosphorylase | 0.2254 | 1 | 1 |
Trypanosoma cruzi | mitogen-activated protein kinase 3, putative | 0.0609 | 0 | 0.5 |
Schistosoma mansoni | uridine phosphorylase | 0.2254 | 1 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 3, putative | 0.0609 | 0 | 0.5 |
Mycobacterium leprae | probable uridine phosphorylase | 0.2254 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 22 nM | Inhibition of murine p38 alpha kinase | ChEMBL. | 12565927 |
IC50 (binding) | = 22 nM | Inhibition of murine p38 alpha kinase | ChEMBL. | 12565927 |
IC50 (functional) | = 60 nM | Inhibition of LPS-induced p38-related TNF-alpha production in human peripheral blood mononuclear cells | ChEMBL. | 12565927 |
IC50 (functional) | = 60 nM | Inhibition of LPS-induced p38-related TNF-alpha production in human peripheral blood mononuclear cells | ChEMBL. | 12565927 |
Inhibition (functional) | = 70 % | Percentage inhibition of the compound against LPS-induced TNF-alpha production in mice at a 10 mg/kg dose | ChEMBL. | 12565927 |
Inhibition (functional) | = 70 % | Percentage inhibition of the compound against LPS-induced TNF-alpha production in mice at a 10 mg/kg dose | ChEMBL. | 12565927 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.